Medtech titan Boston Scientific finally unveils the full results from its PREVAIL study, which was the subject of controversy at last year’s ACC conference.
Boston Scientific (NYSE:BSX) this week unveiled full results from the PREVAIL clinical trial of the Watchman anti-stroke implant, largely agreeing with earlier reports that the device missed a co-primary endpoint for efficacy.
Watchman is a percutaneously delivered cardiac device permanently implanted in the heart’s left atrial appendage to capture clots that may form there.
Hey, check out all the research scientist jobs. Post your resume today!
